Furthermore, PPAR-γ agonists downregulate key pathways of the insulin/IGF axis, such as PI3K/mTOR, MAPK, and GSK3β/Wnt/β-catenin cascades, which regulate cancer cell growth, proliferation, cell reprogramming, and differentiation. Here, GSK3B is linked to cancer.